The United States Court of Appeals for the Fifth Circuit, in New Orleans, has denied an argument by the manufacturer of Reglan that federal law does not allow consumers to file failure-to-warn claims.

Actavis, Inc., the company that manufactures generic Reglan, argued that users of a specific generic Reglan had no legal right to file claims. The court dismissed the case in favor of a woman who now suffers from Tardive Dyskinesia, a rare disorder that causes involuntary and repetitive movement of the lower face and extremities, after using the drug.

The FDA issued a “black box” warning against the drug in February of last year. The warning stated that the drug, used to treat gastroesophageal reflux disease, increases the risk of Tardive Dyskinesia.

If you have taken Reglan and would like to learn more about your legal options regarding side effects, please contact the Reglan lawyers of Williams Kherkher by calling 800-761-3187.